Literature DB >> 15875714

Role of topoisomerases in cytotoxicity induced by DNA ligand Hoechst-33342 and UV-C in a glioma cell line.

Shailja Singh1, B S Dwarakanath, T Lazar Mathew.   

Abstract

DNA ligand Hoechst-33342 significantly enhances UV induced cytotoxicity in human glioma cell lines (BMG-1 & U-87) with supra additive increase in cell death, cytogenetic damage, cell cycle delay, apoptosis and inhibition of PLDR. Cytotoxicity of Hoechst-33342 arises due to its interference in the breakage-rejoining reaction of DNA topoisomerases by stabilization of cleavable complexes. Since topoisomerases have also been implicated in the generation of potentially lethal DNA breaks by interaction with various types of DNA damage including UV induced DNA lesions, we investigated in present studies the role of functional topoisomerases in the synergistic cytotoxicity of Hoechst-33342 and UV in a human glioma cell line (BMG-1). Topoisomerase I activity analyzed by the plasmid relaxation assay, was significantly enhanced upon UV irradiation, implying a possible role of this enzyme in the processing of UV induced lesions. However, this increase in the activity was reduced by >50% in cells incubated with Hoechst-33342 for 1 hr prior to irradiation. Imunoflowcytometric analysis of the chromatin bound topoisomerases I and II levels (cleavable complex) using topoisomerases I and II anti-antibodies showed a good correlation between the induction of apoptosis by Hoechst-33342 and UV and enhancement in the level of topoisomerase II mediated cleavable complexes. Induction of apoptosis was associated with a decline in the level of Bcl2. Taken together, these studies show that supra additive cytotoxic effects of UV-C and Hoechst-33342 in BMG-1 cells are consequences of enhanced stabilization of topo II mediated cleavable complexes and alterations in specific signal transduction pathways of apoptosis, besides the inhibition of topoisomerase mediated repair processes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15875714

Source DB:  PubMed          Journal:  Indian J Exp Biol        ISSN: 0019-5189            Impact factor:   0.818


  2 in total

Review 1.  Experience with irinotecan for the treatment of malignant glioma.

Authors:  James J Vredenburgh; Annick Desjardins; David A Reardon; Henry S Friedman
Journal:  Neuro Oncol       Date:  2008-09-10       Impact factor: 12.300

2.  Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body.

Authors:  Yingfang Fan; Najia Mansoor; Tasneem Ahmad; Rafeeq Alam Khan; Martin Czejka; Syed Sharib; Dong-Hua Yang; Mansoor Ahmed
Journal:  Oncotarget       Date:  2017-07-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.